West Pharmaceutical Services, Inc.
WSTHealthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +57.3%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.
Follow WST
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Dividends and buybacks of $241.3M were more than free cash flow of $150.4M; the difference came from the lines below. Cash rose by $28.3M. Lines the picture does not name came to +$119.7M. What is a cash flow statement?
- Free cash flow
- $150.4M 79.4% of operating cash flow
- Returned to shareholders
- $241.3M 160.4% of free cash flow
- Debt, net
- −$500.0K repaid
- Change in cash
- +$28.3M over the period
| Operating cash flow | 189.5 |
|---|---|
| Capital expenditures | −39.1 |
| Free cash flow | 150.4 |
| Dividends | −15.5 |
| Buybacks, net | −225.8 |
| Debt repaid, net | −0.5 |
| Other | +119.7 |
| Change in cash | 28.3 |
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $251M | $90M | $124M | $190M |
| Capex | −$76M | −$43M | −$43M | −$39M |
| Free cash flow | $175M | $47M | $81M | $150M |
Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
214.00 | 154.00 | 138.80 | 132.10 |
+8 more quarters Free account |
Depreciation & Amortization |
45.90 | 46.20 | 45.20 | 47.00 | |
Non Cash Items (Other) |
(51.10) | 9.80 | 8.80 | (9.70) | |
Change in other assets and liabilities |
(19.30) | (86.00) | (102.90) | 119.70 | |
Operating Cash Flow |
189.50 | 124.00 | 89.90 | 251.10 | |
Capital expenditures |
(39.10) | (43.20) | (42.70) | (76.10) | |
Investing cash flow |
78.90 | (43.20) | (42.70) | (76.10) | |
Repayment/Issuance of Debt (Net) |
(0.50) | 49.60 | (0.30) | (0.30) | |
Equity Repurchase (Common, Net) |
(225.80) | (147.90) | (292.60) | 4.40 | |
Dividends Paid (Total) |
(15.50) | (15.70) | (15.80) | (15.80) | |
Other financial activities |
0.00 | (50.80) | — | 0.00 | |
Financing cash flow |
(241.80) | (164.80) | (308.70) | (11.70) | |
Exchange Rate Adjustment |
1.70 | (1.60) | (8.40) | (0.50) | |
Change in Cash |
28.30 | (85.60) | (269.90) | 162.80 | |
Beginning Cash |
0.00 | 0.00 | 791.30 | 0.00 | |
Ending Cash |
28.30 | (85.60) | 521.40 | 162.80 | |
Stock Based Compensation |
4.30 | 10.90 | 6.60 | 6.70 | |
Dividends Paid (Common) |
(15.50) | (15.70) | (15.80) | (15.80) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(19.30) | (86.00) | (102.90) | 81.70 | |
Issuance/Purchase of Shares |
(225.80) | (147.90) | (292.60) | 4.40 |